Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes

Salman, S; Salman, F; Satman, İlhan; Yilmaz, Y; Ozer, E; Sengul, A; Demirel, HO; Karsidag, KUBİLAY; Dinccag, N; Yilmaz, MT

doi:10.1185/030079901750120231

Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes

Salman S., Salman F., Satman I., Yilmaz Y., Ozer E., Sengul A., ...Daha Fazla

CURRENT MEDICAL RESEARCH AND OPINION, cilt.16, sa.4, ss.296-306, 2001 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 16 Sayı: 4
Basım Tarihi: 2001
Doi Numarası: 10.1185/030079901750120231
Dergi Adı: CURRENT MEDICAL RESEARCH AND OPINION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.296-306
Anahtar Kelimeler: acarbose, gliclazide, type 2 diabetes mellitus, newly diagnosed, ALPHA-GLUCOSIDASE INHIBITORS, 24-WEEK MONOTHERAPY, NIDDM PATIENTS, EFFICACY, MELLITUS, PLACEBO, CARBOHYDRATE, METABOLISM, TOLERANCE, METFORMIN
İstanbul Üniversitesi Adresli: Evet

Özet

Aim: To compare the effect of acarbose and gliclazide on clinical findings, biochemical parameters and safety in type 2 diabetic patients insufficiently controlled with medical nutrition therapy (MNT).